Real-World Evidence

Real-World Evidence Usage in Regulatory Approvals from USFDA and EMA

 

Real-world evidence (RWE) studies can be used at all stages of the product lifecycle and can provide information that complements randomized controlled trials (RCTs) to support clinical, regulatory, and reimbursement decisions. RWE is becoming a part of integrated evidence generation and creating continuity from premarket to iterative post-market approval decisions. The acceptance of RWE for regulatory approval differs across countries. This study identifies and compares the inclusion of RWE as part of an evidence package to support approvals by the United States Food and Drug Administration (USFDA) & European Medicines Agency (EMA).

Contact us at connect@axtria.com with any questions.

Complete the brief form to download the white paper

Recommended insights

RWE Usages in USFDA & EMA Regulatory Approvals Report

Case Study

Long-Term Partnership Helps Advance Real World Evidence in Regulatory and Clinical Decision-Making
RWE Usages in USFDA & EMA Regulatory Approvals Report

White Paper

Digital Twins: A Fit-for-Purpose Solution to Elevate Clinical Trial Power and Efficiency
RWE Usages in USFDA & EMA Regulatory Approvals Report

Article

Evidence at the Forefront: Why Integrated Evidence Planning is Essential for Biopharma Innovation